dilluns, 8 de setembre del 2014

Press Release: Harvard Apparatus Regenerative Technology obtains orphan drug designation from U.S. FDA for HART-Trachea




Entitles company to seven years of marketing exclusivity if device approved by FDA.





Press Release: Harvard Apparatus Regenerative Technology obtains Orphan Drug Designation from U.S. FDA for HART-Trachea

Harvard Apparatus Regenerative Technology (HART)

News Well, Press Release, Regulatory/Clearance, Food & Drug Administration (FDA), New Drug Application (NDA), Regenerative Medicine

read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1tn2Mwb
Publicat per a
Etiquetes de comentaris: ,

Cap comentari:

Publica un comentari a l'entrada

Subscriure's a: Comentaris del missatge (Atom)